Welcome to our dedicated page for QT Imaging Holdings news (Ticker: QTI), a resource for investors and traders seeking the latest updates and insights on QT Imaging Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QT Imaging Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QT Imaging Holdings's position in the market.
QT Imaging (Nasdaq: QTI) completed its first routine FDA inspection with zero Form 483 observations, indicating no cited conditions that may constitute violations of applicable regulations.
The FDA reviewed QT Imaging’s Quality Management System and related operational processes, provided positive feedback on QMS organization and responsiveness, and the company views this as an important operational milestone supporting global commercialization and manufacturing scale-up.
QT Imaging (Nasdaq: QTI) announced that CEO Dr. Raluca Dinu presented the Shiftmaker Award to tennis champion and breast cancer survivor Martina Navratilova during Wimbledon week in London and joined high-profile panels on women’s health, breast health, early detection, and personalized care.
The events, hosted by The Shift, highlight QT Imaging’s commitment to advancing breast health with innovative imaging technologies that provide quantitative information and support more comfortable, patient-centered care.
QT Imaging (Nasdaq: QTI) reported multi-site data supporting strong reproducibility of its Breast Acoustic CT scanner’s quantitative biomarkers. Speed of Sound (SoS) measurements showed less than 1% variability within and across scanners, while volumetric metrics had about 5% variability for Total Breast Volume and 12% for FGV/TBV.
The study, conducted at two clinical sites with five patients per site scanned five times each, suggests this reproducibility can support longitudinal breast imaging and quantitative, data-driven breast health assessment.
QT Imaging (Nasdaq: QTI) received Saudi Food and Drug Authority clearance for its Breast Acoustic CT™ scanner, allowing marketing, sales, and deployment across Saudi Arabia. The approval enables commercial rollout under its exclusive distribution agreement with Gulf Medical Co. and supports QT Imaging’s expansion strategy in the Gulf region.
With regulatory clearances in both Saudi Arabia and the United Arab Emirates, QT Imaging has created a commercial foundation in the two largest healthcare markets in the Gulf, targeting growing demand for radiation-free, compression-free 3D breast imaging.
QT Imaging (Nasdaq: QTI) is expected to be added to the Russell Microcap® Index, based on the preliminary additions list dated May 22, 2026. Final inclusion will follow completion of the 2026 Russell indexes reconstitution and, if affirmed, take effect at the U.S. market open on June 29, 2026.
The Russell Microcap Index tracks the microcap segment of the U.S. equity market and is widely used as a benchmark. Membership, according to QT Imaging, can enhance visibility, broaden exposure to institutional investors and index strategies, and brings automatic inclusion in applicable Russell growth and value style indexes.
QT Imaging (Nasdaq: QTI) closed a previously announced underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants) for gross proceeds of about $10 million.
According to QT Imaging, net proceeds will support working capital and general corporate purposes.
QT Imaging (Nasdaq: QTI) priced an underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants) at $5.00 per share, for expected gross proceeds of $10 million before fees.
The offering is expected to close on or about May 18, 2026. According to QT Imaging, net proceeds will support working capital and general corporate purposes, alongside a recently extended senior secured term loan maturity.
QT Imaging (Nasdaq: QTI) reported first quarter 2026 revenue of $6.5 million, up 133% year-over-year, driven by shipment of 13 Breast Acoustic CT scanners. Gross margin was 41%, and net loss narrowed to $3.4 million from $11.1 million.
The company reaffirmed 2026 revenue guidance of ~$39 million, extended its senior secured term loan maturity to March 31, 2029, secured a dedicated Category III CPT code effective January 2027, obtained FDA 510(k) clearance for scanner enhancements, and confirmed UAE regulatory clearance supporting a multiyear agreement for at least 43 scanners totaling over $24 million.
QT Imaging (Nasdaq: QTI) appointed leading breast surgical oncologist Dr. Barry Roseman as Senior Medical Advisor.
He will implement QT Imaging’s radiation-free, 3D breast imaging technology in a high-volume diagnostic and screening center, supporting physician training, workflow integration, patient access, and real-world data collection.
QT Imaging (Nasdaq: QTI) will report financial results for the quarter ended March 31, 2026 after market close on Wednesday, May 13, 2026, and will host an investor conference call the same day at 4:30 p.m. ET / 1:30 p.m. PT.
Participants may pre-register to receive a passcode and PIN; dial-in numbers are provided for U.S. and international callers. A live and archived webcast will be available on the company investor relations calendar.